Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China

Junji Zhang,Yuqian Zhao,Yi Dai,Le Dang,Li Ma,Chunxia Yang,Yang Li,Linghua Kong,Lihui Wei,Shulan Zhang,Jihong Liu,Minrong Xi,Long Chen,Xianzhi Duan,Qing Xiao,Guzhalinuer Abulizi,Guonan Zhang,Ying Hong,Xiaohong Gao,Qi Zhou,Xing Xie,Li Li,Mayinuer Niyazi,Zhifen Zhang,Jiyu Tuo,Yiling Ding,Manfei Si,Fei Chen,Li Song,Youlin Qiao,Jinghe Lang
DOI: https://doi.org/10.1001/jamaoncol.2020.6575
IF: 33.006
2021-02-01
JAMA Oncology
Abstract:<h3>Importance</h3><p>Evidence is needed regarding the introduction of high-risk human papillomavirus (hrHPV) testing into China's national cervical cancer screening program.</p><h3>Objective</h3><p>To evaluate hrHPV testing as a new screening modality for the national program.</p><h3>Design, Setting, and Participants</h3><p>This population-based, multicenter, open-label, randomized clinical trial took place across 20 primary health care centers in urban and rural areas across China. At least 3000 women aged 35 to 64 years per site were invited to participate, for a total of 60 732 women evaluated.</p><h3>Interventions</h3><p>At baseline, women were randomly assigned to cytology, hrHPV testing, or visual inspection with acetic acid and Lugol iodine (VIA/VILI) (rural only). Women who tested positive for hrHPV were randomized into cytology-triage, VIA/VILI-triage (rural only), or direct colposcopy arms. Regarding primary or triaging tests, women with cytological abnormalities or who tested positive with VIA/VILI were referred to colposcopy. After 24 months, combined screening of cytology, hrHPV testing, and VIA/VILI was performed, and all women with positive results were referred to colposcopy.</p><h3>Main Outcomes and Measures</h3><p>The primary outcomes were cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and CIN3+ yields. The secondary outcome was colposcopy referral rate.</p><h3>Results</h3><p>A total of 60 732 women were included in this study, with median (interquartile range) age of 47 (41-52) years. Among urban women, 8955 were randomized to cytology and 18 176 to hrHPV genotyping; among rural women, 11 136 were randomized to VIA/VILI, 7080 to cytology, and 15 385 to hrHPV testing. Participants who tested positive for hrHPV with direct colposcopy had higher risk ratios for disease yields at baseline (urban hrHPV vs cytology, CIN2+ 2.2 [95% CI, 1.6-3.2] and CIN3+ 2.0 [95% CI, 1.2-3.3]; rural hrHPV vs cytology, 2.6 [95% CI, 1.9-4.0] and 2.7 [95% CI, 2.0-3.6]; rural hrHPV vs VIA/VILI, 2.0 [95% CI, 1.6-2.3] and 2.3 [95% CI, 1.8-3.1]). At 24 months, baseline-negative women in the hrHPV arm had significantly lower risk ratios than those with cytology, or VIA/VILI for CIN2+ (0.3 [95% CI, 0.2-0.5], 0.3 [95% CI, 0.2-0.6]) and CIN3+ (0.3 [95% CI, 0.1-0.6], 0.4 [95% CI, 0.2-0.8]) in rural sites. The colposcopy referral rate for hrHPV-positive rural women was reduced to 2.8% by cytology triage, with significantly higher CIN2+ yields than cytology (2.1 [95% CI, 1.3-2.6]) or VIA/VILI arm (1.6 [95% CI, 1.03-2.1]). Genotyping for hrHPV with cytology triage significantly reduced the colposcopy referral rate compared with cytology (0.8 [95% CI, 0.7-0.9]) for urban women.</p><h3>Conclusions and Relevance</h3><p>In this randomized clinical trial, testing for hrHPV was an effective primary screening method in primary health care centers. Incorporating hrHPV testing (polymerase chain reaction–based for urban areas, hybrid capture-based for rural areas) into China's national screening program is reasonable.</p><h3>Trial Registration</h3><p>Chinese Clinical Trial Registry Identifier:ChiCTR1900022530</p>
oncology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the effectiveness of high - risk human papillomavirus (hrHPV) testing as a new primary screening method in China's cervical cancer screening program. Specifically, the study aims to compare the performance of hrHPV testing with traditional cytological examination (Pap smear) and visual inspection with acetic acid and iodine staining (VIA/VILI) under the routine screening conditions in primary health care centers, especially the applicability and effectiveness in urban and rural areas. ### Research Background - **Cervical Cancer Problem**: Cervical cancer leads to relatively high morbidity and mortality in low - and middle - income countries. In 2009, China launched a major plan to curb cervical cancer and expanded the national screening program in 2012, but the actual public health needs covered by this program are less than 30%. - **Existing Screening Methods**: Currently recommended primary screening methods include cytological examination and VIA/VILI, but the effectiveness of these methods is limited. - **Advantages of hrHPV Testing**: Multiple studies have shown that hrHPV testing is more effective in screening for cervical cancer than cytological examination, especially in detecting cervical intraepithelial neoplasia (CIN2+ and CIN3+). ### Research Design - **Trial Type**: This is a multi - center, open - label, randomized clinical trial. - **Participants**: In 20 urban and rural primary health care centers in China, at least 3,000 women aged 35 to 64 were invited to participate, and a total of 60,732 women were evaluated. - **Interventions**: Women were randomly assigned to cytological examination, hrHPV testing, or VIA/VILI (only in rural areas). Women with positive hrHPV tests were further randomly assigned to cytological triage, VIA/VILI triage (only in rural areas), or direct colposcopy. ### Main Results - **Primary Outcomes**: Detection rates of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) and grade 3 or more severe (CIN3+). - **Secondary Outcomes**: Colposcopy referral rates. ### Research Findings - **Baseline Screening Results**: - In urban areas, the CIN2+ and CIN3+ detection rates in women with positive hrHPV tests were 2.2 times (95% CI, 1.6 - 3.2) and 2.0 times (95% CI, 1.2 - 3.3) those of cytological examination respectively. - In rural areas, the CIN2+ and CIN3+ detection rates in women with positive hrHPV tests were 2.6 times (95% CI, 1.9 - 4.0) and 2.7 times (95% CI, 2.0 - 3.6) those of cytological examination respectively, and 2.0 times (95% CI, 1.6 - 2.3) and 2.3 times (95% CI, 1.8 - 3.1) those of VIA/VILI respectively. - **24 - month Follow - up Results**: - Among women with negative baselines, the risks of CIN2+ and CIN3+ in the hrHPV testing group were significantly lower than those in the cytological examination group or the VIA/VILI group. - In rural areas, the colposcopy referral rate of women with positive hrHPV tests after cytological triage decreased to 2.8%, and the CIN2+ detection rate was significantly higher than that in the cytological examination group (2.1 [95% CI, 1.3 - 2.6]) or the VIA/VILI group (1.6 [95% CI, 1.03 - 2.1]). ### Conclusions - **Effectiveness of hrHPV Testing**: This randomized clinical trial conducted in primary health care centers shows that hrHPV testing is more effective in detecting CIN2+ and CIN3+ as a primary screening method than cytological examination or VIA/VILI. - **Rationality of Inclusion in the National Screening Program**: It is reasonable to include hrHPV testing (polymerase chain reaction - based testing in urban areas and hybrid capture - based testing in rural areas) in China's national screening program. ### Significance - **Improving Screening Coverage**: hrHPV testing can increase the detection rate of high - risk CIN cases, reduce missed diagnoses, and thus improve the overall effectiveness of cervical cancer screening. - **Resource Optimization**: By reducing unnecessary colposcopies, hrHPV testing can optimize the use of medical resources, especially in resource - limited rural areas. ### Limitations - **Short Screening Interval**: The short interval between two screenings limits further evaluation of women with negative baselines.